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Glycopolymers, synthetic polymers displaying carbohydrate moieties, have been linked to many
potential applications at the biology–chemistry interface. One area that holds particular promise is
the employment of glycopolymers as vehicles for therapeutics or as therapeutics themselves. This
review summarises some of the more prominent examples as well as those in the early stages of
development.10
Introduction
Glycopolymers,1-3 synthetic polymers featuring pendant
and/or terminal carbohydrate moieties, have been of particular
interest to the field of drug delivery and therapeutics. This
interest is derived from the complex roles that carbohydrates15
play in vivo, particularly in recognition events with
carbohydrate-binding proteins known as lectins.4, 5 The
interaction between lectins and carbohydrates is weak;
dissociation constants, Kd, are typically 10-3–10-6 M, but may
be greatly enhanced, in a non-statistical manner, through20
multivalency. This phenomenon has become known as the
cluster glycoside effect.6 As polymers are, typically,
multivalent by definition, they provide simple methodologies
for accessing this effect. The ubiquitous nature of lectins
within recognition and binding events suggests great potential25
for their exploitation as drug targets and at least one review
on the subject has already been published.7 Additionally,
glycopolymers provide easily synthesisable analogues of
naturally occuring polysaccharides. Several targets for
glycopolymeric drugs (some lectin-based and some not) have30
been identified, including influenza, Alzheimer’s disease and
some cancers. Herein, we review some of the glycopolymeric
drugs8 and drug-delivery systems9-11 developed to date.
Glycopolymeric Drugs
Influenza hæmagglutinin and neuraminidase inhibitors35
One class of disease-carrying agent that has received
considerable attention as a target for glycopolymeric
treatments are the influenza viruses. Considering their
abundance and the number of fatalities that these viruses can
cause - tens of thousands of deaths are attributed to influenza40
each year in the USA alone12 - the search for effective
treatments is unsurprising.
Influenza infection is a multistep process: initially, the virus
binds to N-acetyl neuraminic acid residues on the target cell
via lectin structures known as hæmagglutinin (HA) fingers on45
its surface membrane and then enters the cell via endocytosis.
The virus membrane then fuses with the endosome releasing a
complex of RNA and proteins into the cytoplasm. These are
transported into the nucleus and the process of virus
replication begins.13 If initial binding of the virus to the cell50
can be prevented, subsequent uptake and replication can also
be halted. A molecule that could block HA binding efficiently
could prove a useful prophylactic during influenza breakouts,
such as the recent H1N1 pandemic. Influenza hæmagglutinin,
like most lectins, has a shallow binding site and its interaction55
with monovalent sialosides is typically weak (Kd~2 mM),14
thus multivalent ligands should provide improved avidity.
Additionally, the virus surface presents a neuraminidase (NA)
enzyme and consequently hæmagglutinin inhibitors need to be
stable with respect to neuraminidase action.15, 1660
The first example of an influenza hæmagglutinin inhibitor
(HAI) based around a glycopolymer was reported by Bovin et
al. in 1990. Polymeric sialosides of varying carbohydrate
densities were synthesised by the reaction between poly[4-
nitrophenylacrylate] with monosialosides with amino-65
terminated linkers (Fig. 1). As would be expected, little or no
inhibition was seen for monovalent sialosides, -sialosides, or
polymers carrying low quantities of -sialoside residues
(5%). Increasing the sialoside density from 10 through to
30% indicated a maximum in inhibition at 20%, with 30%70
having a lower inhibitory effect than the 10% sialylated
polymer.17
Figure 1: Synthesis of polymeric multivalent sialosides as used by Bovin
et al. 1775
The main contributors to the field of glycopolymeric HAIs are
Whitesides and collaborators. Throughout the 1990s
Whitesides et al. published several studies on the inhibition
activity of polymeric sialosides synthesised by both
polymerisation of sialylated monomers and post-80
polymerisation functionalisation of reactive polymers.18-23
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Figure 2: Sialic acid derived monomers and amines as used by Whitesides
et al. in the synthesis of glycopolymeric influenza hæmagglutinin
inhibitors. See Fig. 1 for structure of sialic acid (SA).
Initial studies involved copolymers of acrylamido -O-
sialoside (1, Fig. 2) with various N-substituted acrylamides.5
As Bovin et al. had described previously,17 a maximum level
of inhibition was observed at intermediate levels of
sialylation. This was rationalised by the competition between
cooperative and efficient binding of the sialic acid groups: at
low SA levels the groups are well separated and thus binding10
of one residue does not increase the likelihood of a subsequent
group’s binding; with high SA levels, binding may be limited
as the steric bulk of the groups overcrowd one another. It was
also noted that bulky or charged groups on the comonomer
tended to reduce the binding efficiency and, in turn,15
inhibition.19, 23 Although copolymers of 1 resulted in highly
effective HAIs (inhibition constants (KiHAI) were typically
104–105 fold greater than monomeric equivalents on a per
sugar basis), the O-linked SA made them susceptible to
cleavage by neuraminidases. In order to alleviate this20
problem, acrylamido -C-sialoside 2 was synthesised and
copolymerised with acrylamide. Polymers with C-linked SA
groups were found to have a maximum inhibitory effect
comparable to that of their O-linked equivalents and had a far
greater effect at low SA concentrations, probably due to their25
ability to interact with neuraminidase without deactivation.21
Despite high levels of inhibition displayed by polymers
synthesised from sialylated monomers, they were still less
efficient than either non-polymeric synthetic HAIs, such as
sialylated liposomes,24 or naturally occurring HAIs, such as30
equine α2-macroglobulin,25 KiHAI~100–200 nM. Consequently,
Whitesides et al. turned their attention to the sialylation of
reactive polymer backbones. The reasons for this are three-
fold: firstly, due to differing monomer reactivities, it is
unlikely that sialosides will be statistically placed along a35
polymer based upon feed ratio. If the comonomer is of higher
reactivity it is likely that, especially at the low feed level of
SA monomers, the result would be gradient copolymers.
Secondly, as overcrowding was considered to be responsible
for the reduction in activity of polymers containing greater40
quantities of SA, steric interactions should reduce over-
functionalisation. Finally, polymers may be more directly
compared; a single batch of a precursor polymer results in all
derivative polymers having the same polydispersity and
degree of polymerisation.45
The precursor polymers of choice were those featuring
activated esters,26, 27 such as poly[N-(acryloyloxy)
succinimide] (pNAS) or poly[acrylic anhydride] (pAAn),
which were reacted with amino-terminated sialosides
including 3 and 4. pNAS was treated with a varying number50
of equivalents of 3 from 0.2–1.2 with respect to the number of
succinimide groups; the level of sialoside incorporation was
found to correlate directly with the number of sialoside
equivalents up the maximum value of 1. After reaction of the
sialoside, any remaining succinimide groups were55
functionalised by addition of an excess of a second amine or
ammonia to yield copolymers of various N-substituted
acrylamides. As was seen with the previous polymers,
addition of charged groups had a negative effect on the
inhibition, particularly positive charges where a singly60
positively charged side group has a more detrimental effect
than a triply negatively charged side group; neutral, polar side
groups also reduced inhibition with increasing steric bulk.
Hydrophobic side groups increased or decreased inhibition
depending on the steric bulk. Benzylamine, for example, was65
found to improve efficacy as its level of incorporation was
increased; presumably through increased hydrophobic–
hydrophobic interactions between the polymer and virus
surface. Conversely, hexylamine resulted in reduced
inhibition.20 Overall polymers with sub-nanomolar values of70
KiHAI could be produced. Polymers synthesised by similar
methods from pAAn gave similar results.18 It was also
determined that a synergistic treatment combining C-
sialoside-acrylamide copolymers and low molecular weight
monomeric neuraminidase inhibitors resulted in even greater75
inhibition of hæmagglutination. Although the mechanism of
this synergy was not confirmed it is thought that the NA
inhibitor displaces the polymer from the NA sites either
allowing more SA residues to bind to HA sites or increasing
the overall steric bulk of the polymer around the virus.2880
In addition to hæmagglutinins, the neuraminidases are also
targets for influenza treatment; in fact, the currently preferred
influenza antivirals, such as oseltamivir (Tamiflu®, Hoffman-
La Roche) and zanamivir (Relenza®, GlaxoSmithKline), act
as transition state analogues of sialic acid cleavage.29 The85
presence of NAs on influenza at first seems counterproductive
for the virus; NAs cleave sialic acid residues which would, in
effect, reduce the chance of viral binding to the cell surface.
In fact, the neuraminidases are essential for spread of the
virus and infection of further host cells. Once a replicated90
virus has matured and budded from the cell, it can once again
bind to the cell surface via the hæmagglutinin molecules. The
neuraminidase cleaves the cell surface sialic acid groups,
releasing the new virus.30 Multivalent sialosides that are
SA S
N
H
O
SA
O
O N
H
O
O O
N OO
n
O
n
NH
R
RNH2
SA
O
O
N
H
NH2
O
HN
S
O
O
NMe2
SA S
NH2 3
4
1
2
This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00 | 3
resistant to NAs have the potential of binding to these
receptors and preventing the release of the virus from the host
cell and therefore limiting the infection.
Linhardt et al. synthesised C-linked glycopolymer 5 (Fig. 3)
and tested its ability to inhibit neuraminidase from5
Clostridium perfringens, a common bacterium. 5 was
synthesised by enzymatic polymerisation of the aromatic
monomer by soy bean peroxidase in the presence of hydrogen
peroxide. 5 was seen to inhibit neuraminidase 10-fold greater
than monomeric equivalents.31 Matsuoka et al. synthesised 610
as a copolymer by radical polymerisation of an acetate-
protected vinyl precursor with vinyl acetate; after treatment
with NaOH, sialylated poly[vinyl alcohol] was isolated. In
preliminary tests, polymers were shown to have an inhibitory
effect against influenza neuraminidases in the millimolar15
range.32 Dendritic sialosides synthesised by the same group
display similar levels of inhibition.33
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Figure 3: Polymeric neuraminidase inhibitors as synthesised by
Linhardt et al. (5) and Matsuoka et al. (6). SA = -sialoside, structure20
given in Fig. 1.
Human immunodeficiency virus
Figure 4: Sulfated maltoheptaose derived methacrylate glycopolymers as25
synthesised by Yoshida et al.
Human immunodeficiency virus (HIV) infection is now a
major international pandemic and is estimated to have killed
25 million people through progression to acquired
immunodeficiency syndrome (AIDS). It is estimated that30
between 30 and 36 million people are currently infected with
HIV and between 2.2 and 3.2 million people were infected in
2007.34 One area of interest for the development of improved
HIV treatments is the use of anionic polysaccharides which
have been shown to prevent HIV binding to the CD-435
receptor, and thus its entrance to the host cell, in vitro.35
Yoshida et al. synthesised methacrylate polymer 7 (Fig. 4)
with maltoheptaose pendant groups by polymerisation of the
peracetylated monomer followed by deacetylation and
sulfation with either piperidine-N-sulfonic acid or SO3-DMF40
complex. The polymers were assayed for their ability to
inhibit the infection of MT-4 cells by HIV. HIV inhibition
was seen to increase with increasing polymer chain length and
degree of sulfation for homopolymers but was poor compared
to naturally derived polysaccharides such as dextran and45
curdlan sulfates. Copolymers with methyl methacrylate
(MMA) increased in inhibitory effect as the number of
maltoheptaose groups was reduced. At approximately 80%
MMA the copolymers displayed inhibition in the same order
of magnitude as the polysaccharides. Although the level of50
inhibition is still 2 orders of magnitude worse than that of
azidothymdine, a common anti-retroviral, these materials
display reduced cytotoxicity in comparison and may have
potential in the future.36
Alzheimer’s Disease55
Alzheimer’s disease (AD) is a neurodegenerative disorder that
is the leading cause of dementia of which there are an
estimated 24 million sufferers worldwide, a figure that is
expected to rise to over 80 million by 2040.37 Alzheimer’s
disease is characterised pathologically by the accumulation of60
senile plaques; insoluble aggregates of misfolded amyloid -
peptide (A). One of the current hypotheses for the
progression of AD is that these plaques,38 or soluble
precursors as small as dimers,39-41 are neurotoxic resulting in
atrophy of brain tissue; A itself is considered harmless.65
Prevention of amyloid- aggregation may slow, or stop, brain
degeneration. Although the underlying cause and mechanism
of A misfolding and plaque formation is still the subject of
debate there have been several reports of glycoconjugates,
such as gangliosides and glycosaminoglycans accelerating70
aggregation of A, potentially by acting as templates on
which the process may occur.42-46 In an attempt to understand
further the interaction between glycosaminoglycans and A,
Miura et al. synthesised glycopolymeric mimics by
copolymerisation of glycomonomers 8 and 9 with acrylamide.75
In contradiction of the expected result, polymers containing
relatively small quantities of monomer 9 (10–30%) were seen
to reduce the level of A aggregation and the morphology of
those aggregates that did form; no appreciable effect was
observed for polymers of 8. Cytotoxicity of A to HeLa cells80
was found to be significantly reduced by addition of a
copolymer containing 11% of 9, presumably through reduced
Aaggregation; the polymer itself was found to be non-
cytotoxic.47
85
Figure 5: Glucosamine based glycomonomers as synthesised by Miura et
al.47
Glycopolymeric drug-delivery
One of the greatest problems facing pharmaceutical
development is the production of an efficacious drug that does90
not produce undesirable side effects; patient death being the
least desirable of all. Side effects are usually the product of a
drug having little or no selectivity with regard to its site of
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action or poor pharmacokinetics, where the drug is cleared
from the body too quickly requiring either larger doses or
regular administration in order to keep the treatment at an
adequate level. Poor pharmacokinetics are a particular
problem with anti-tumour drugs which, by their very nature,5
are usually cytotoxic and thus doses must be accurately
controlled in order to destroy the tumour without disrupting
healthy cells. The importance of dosage is clear when one
considers methotrexate, a widely used anti-tumour drug, the
use of which often requires the subsequent administration of a10
‘rescue drug’, folinic acid or its salts, to prevent methotrexate
toxicity.48 Another major obstacle in drug delivery is the
blood-brain barrier (BBB), which is remarkably efficient at
preventing the diffusion of molecules into the brain. The walls
of the majority of the capillaries in the body consist of15
endothelial cells with small pores between, known as
fenestræ, which allow small molecules to diffuse between the
blood stream and surrounding tissues and vice versa. The
capillary walls of the blood brain barrier have no such
fenestræ and consequently transport through the BBB must be20
via the lipid membrane or some form of transport protocol.
This is well demonstrated in Fig. 6 which shows a full body
radiogram of a mouse 30 min. after injection with
radiolabelled histamine; the histamine enters all organs of the
body except the brain and spinal column.49 Glycosylation has25
recently been shown to be effective at enabling peptides,50
proteins51, 52 and nanoparticles53 to cross the BBB. Currently
this area is poorly understood and the mechanism of transport
is unknown. Consequently such methodologies may not be
considered generally applicable but may provide a route for30
allowing delivery to the brain. In order to combat the
problems outlined above, methodologies for site-specific
delivery of drugs are required.
Figure 6: Autoradiogram of an adult mouse 30 min. after intravenous35
injection of radiolabelled histamine. The dark regions show where the
histamine is located - none is detected in the brain and spinal cord
regions. Reprinted from NeuroRX, Vol 2, Pardridge, W. M., The Blood-
Brain Barrier: Bottleneck in Brain Drug Development, 3-14, Copyright
(2005), with permission from The American Society for Experimental40
NeuroTherapeutics, Inc. Published by Elsevier Inc.
Carbohydrate targeting
In the mid-1970s Ringsdorf introduced a simple model for the
polymeric delivery of drugs, a so-called ‘magic bullet’
method. The Ringsdorf model is remarkably simple. Attached45
to a polymer backbone are three types of group: a targeting
moiety, a solubilising moiety and, via a cleavable linker, the
drug to be delivered (Fig. 7).54 In the case of glycopolymers
the carbohydrate moieties may act as both the targeting
vector, specific to a lectin on the surface of the tissue to be50
treated, as well as aiding solubility. There are now
approximately 20 drugs either on the market or in clinical
trials based upon this type of model.55
Figure 7: The Ringsdorf model for drug delivery by polymers.
55
An example of such a treatment has been demonstrated by
Hashida et al. in mice. The K vitamins are a family of
hydrophobic molecules required for the synthesis of the
proteins involved in blood coagulation.56 The denotation of
‘K’ vitamins derives from the German naming koagulations60
vitamin,57 consequently vitamin K deficiency may lead to
hæmorrhaging. It is common for expectant mothers and
newborns to be administered vitamin K as a prophylactic but
this has found controversy due to its administration having
been weakly linked to childhood cancers and other side65
effects.58, 59 The majority of coagulating proteins are
synthesised in the liver and thus targeted delivery of vitamin
K to the liver may allow suitable prophylaxis with reduction
of potential side effects. Hepatic (liver) cells are known to
express the galactoside-binding asialoglycoprotein receptor70
(ASGPR) on their surface; on binding, the galactoside-
conjugate is internalised by the cell.60 Hashida et al.
synthesised terpolymers based upon a poly[L-glutamic acid]
(PLGA) backbone (Fig. 8) by reaction with ethylenediamine
followed by 2-imino-2-methoxyethyl 1-thiogalactoside to75
produce galactosylated PLGA. In turn, this was reacted with
vitamin K5, a synthetic K vitamin analogue, to yield a
galactosyl-PLGA-vitamin K conjugate. The anti-hæmorhaggic
effect of such polymers was determined in mice models by
comparison of the prothrombin time, a measure of coagulation80
efficiency, after systemic treatment with warfarin. As
expected, in all cases prothrombin time was increased for
warfarin treated mice compared with untreated. Warfarin
treated mice that received intravenous (IV), unconjugated
vitamin K only had a statistically significant reduction in85
prothrombin time 4 h after treatment, those receiving IV
galactose-PLGA-K conjugate had a significant reduction at 2,
3 and 4 h time points.61
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Figure 8: Anti-hæmorrhagic, poly[L-glutamic acid] based terpolymers as
synthesised by Hashida et al.
Similarly Fleming et al. have targeted boar spermatozoa,
which are known to display a galactose-binding lectin with
great similarity to the hepatic ASGPR, with galactosyl5
polymers in vitro. They synthesised terpolymers of 2-(-D-
galactosyloxy)ethyl methacrylate, 2-(dimethylamino)ethyl
methacrylate (DMAEMA) and a methacrylate featuring an -
tocopherol functionality. The resulting polymers were
incubated with spermatozoa in an attempt to deliver the -10
tocopherol, an antioxidant, to the cells to reduce oxidative
damage during storage. Although the polymers appeared to
have some protective effect to confirm their entrance into the
cells, rather than acting as an extra-cellular protectant, the -
tocopherol monomer was replaced by a fluorescent monomer,15
hostasol methacrylate, and the polymer inside the cell
visualised by confocal microscopy (Fig. 9).62
Figure 9: Confocal micrograph of boar spermatozoa after incubation with
a poly[GalEMA-DMAEMA-hostasol methacrylate] terpolymer. Image20
provided by the author.
PK2: glycopolymers in clinical trials
The field of polymeric vectors for drug delivery has been
dominated by work of Duncan, Kopeček and Seymour. The 
most well known of their polymers – PK1, an untargeted25
doxorubicin conjugate, has been evaluated in Phase II clinical
trials for breast, lung and colorectal cancers.63 Typically, they
synthesised copolymers of N-(2-hydroxypropyl)
methacrylamide (HPMA) and a second monomer featuring an
active ester, such as a p-nitrophenyl ester, as a pendant group;30
the active ester was linked to the polymerisable moiety by a
peptide linker, Gly-Gly or Gly-Phe-Leu-Gly for example.
These polymers were then reacted with the ‘drug’ to be
delivered and a glycosamine in order to provide targeting.
Initial studies used model drug compounds such as35
tyrosinamide which were radiolabelled to allow easy detection
of their relative biodistribution. The radiolabelled polymers
were administered intravenously to rats and blood
radioactivity levels were measured at regular intervals. After a
set time (1 or 5 h) the rats were sacrificed and radioactivity40
levels of individual organs assayed. When the polymers
beared galactosamine moieties, 90% clearance of the polymer
from the bloodstream was seen within 1 hour and nearly 70%
was seen to be present in the liver. Polymers featuring gluco-
or mannosamine moieties, or control polymers with a simple45
amine, were seen to be cleared from the bloodstream more
slowly with 10% accumulating in the liver. For all polymers,
after 5 h  80% of radioactivity was to be found in the urine
and faeces.64, 65
Figure 10: Structure of doxorubicin-conjugated polymer PK2. The trace50
tyrosinamide modifications are omitted for clarity.
A polymer based upon this model, PK2 (FCE28069, Fig. 10),
with the majority of tyrosinamide replaced with the anti-
tumour drug doxorubicin (DOX) has been evaluated in a
Phase I clinical trial for hepatoma. Trace levels of55
tyrosinamide were maintained to facilitate radiolabelling and
subsequent imaging. Doxorubicin is a highly effective
chemotherapy drug, however off-target cardiotoxicity limits
its use.66, 67 A preclinical study in a rat model was used to
determine the level of cardiotoxicity c.f. free DOX. PK2 and60
free DOX were administered by both IV and intraperitoneal
(IP) injection. Acute and cardiovascular toxicities were
montitored by weight loss and cardiac output respectively.
Animals receiving free DOX IV displayed acute toxicity at
doses greater than 2 mg/kg, with significant (>20%) weight65
loss 8–12 weeks after administration. By comparision,
animals treated with PK2 at up to 12 mg/kg (DOX equivalent)
were seen to gain weight, albeit at a reduced rate compared to
the saline control. IP administration was considerably less
toxic for both PK2 and free DOX, with no mean weight loss70
after 12 weeks. Animals administered 12 and 18 mg/kg DOX
equivalents of PK2 gained weight at a comparable rate to the
saline controls. Cardiotoxicity, measured by relative cardiac
output, was found to be insignificant in IV doses of PK2 up to
12 mg/kg and free DOX at 2 mg/kg. 3 mg/kg DOX yielded75
significant decreaes in cardiac output (>35%, p<0.0005) after
12 weeks. No animals survived to the 12 week end-point when
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administered 4 mg/kg DOX IV. Overall survival curves
showed that all animals receiving IV PK2 survived to 12
weeks post-administration. IP administration was, again, seen
to be far less toxic with only doses of 5 and 6 mg/kg of DOX
or 36 mg/kg PK2 resulting in less than 80% survival at 125
weeks.68
PK2 was assessed in a Phase I clinical trial involving patients
with confirmed primary or secondary solid hepatic tumours.
Patients were administered PK2 IV at 3 week intervals for a
maximum of 6 treatment cycles. Doses administered ranged10
from 20–160 mg/m2 DOX equivalent. Blood and urine
samples were collected at various times up to 8 days after
each treatment. Blood and urine samples were analysed to
determine the level of polymer-bound and free doxorubicin
and metabolites; distribution of the polymer was determined15
by full body imaging of 123I using single photon emission
computed tomography. The galactosamine-polymer-
doxorubicin conjugate was seen to be rapidly cleared from the
bloodstream with 15–20% of the administered dose
accumulating in the liver after 24 h. A control polymer,20
identical except for the absence of galactosamine residues,
was seen to remain in the bloodstream for longer and was
found to have a general body distribution with no organ
specificity. Despite a large accumulation of the polymer in the
liver the majority was found in healthy hepatic cells rather25
than in the tumours themselves, although the accumulation
was still significant compared to background. The reduced
uptake to cancerous cells was rationalised by the reduced
levels of ASGPR that hepatoma cells are known to express
compared to their healthy counterparts.69-72 The increased30
uptake compared to other tissues may instead be due to the
enhanced permeability and retention effect and not a result of
lectin targeting.73
Glycosylated Micelles
35
Figure 11 – Amphiphilic polycarbonate block copolymers as used by
Hedrick et al. for the delivery of doxorubicin
Heldrick et al. recently described glycopolymeric micelles
assembled from an amphiphilic, glycosylated polycarbonates40
(Fig. 11). The micelles were loaded with DOX and its delivery
to HepG2 and HEK293 cell lines in vitro was studied using
flow cytometry. In the HEK293 cells (ASGPR negative) no
difference was seen between free DOX and either of the
glycosyl micellar formulations. In HepG2 cells (ASGPR45
positive) a three-fold increase in uptake was observed for the
galactosyl formulation over the glucosyl formulation and free
DOX. The galactose-specific targeting was confirmed by a
dose-responsive reduction in uptake when cells were pre-
treated with asialofetuin, a galactose-presenting protein.7450
Glycopolymeric Chaperones
The difficulties in effective drug-delivery are apparent when
the payload to be delivered is a protein or nucleic acid for
which the immune system is a veritable minefield. Ideally, a
suitable drug-delivery system for such molecules would55
provide protection from degradation and a means of targeting
the payload to a specific site. The simplest method of
introducing a gene or other biomolecule into a cell is direct
microinjection but this is hardly practical for the treatment of
large multicellular organisms such as humans. The use of60
viruses, modified to carry the nucleic acid sequence of choice,
allows efficient delivery but involves the use of potentially
pathogenic precursors and nucleic acid strand length may be
limited. Non-viral delivery vectors have the potential to
replace viral vectors with non-immunogenic, low cost and65
easily produced materials.75
Figure 12: Glycosylated monomers as used by Chaikof et al. for the
synthesis of heparin mimics via cyanoxyl-mediated polymerisation.
The use of glycopolymers as molecular chaperones for
proteins has been demonstrated by Chaikof et al. They utilised70
cyanoxyl-mediated polymerisation76, 77 for the synthesis of
several biomimetic glycopolymer species from alkenyl,
acryloyl and acrylamido glycomonomers, often in their
sulfated form (Fig. 12).76, 78-80 Several of these polymers were
tested with respect to their ability to act as mimics of heparan75
sulfates.79 In vivo, fibroblast growth factor 2 (FGF-2) is bound
by heparan sulfate, an anionic polysaccharide, which acts as a
molecular chaperone protecting FGF-2 from deactivation and
facilitating its binding to FGF receptor-1 (FGFR-1).81 Binding
assays found that polymers featuring N-acetylglucosamine80
residues did bind, but weakly compared to heparan sulfate, the
linker length was seen to have little effect.79 Sulfated sugars
bound more strongly than their non-sulfated equivalents,
particularly for polymers featuring pendant lactose groups.
Further investigation into the FGF-2 chaperone role of85
glycopolymers featuring lactose sulfate residues found that
low molecular weight (10 kDa) polymers containing ca. 10%
of the glycomonomer were nearly as effective as heparin in
dimerising FGF-2 and binding it to FGFR-1. The chaperone
qualities of the polymer were also demonstrated by the extra90
stability that it gave FGF-2 with respect to degradation by
acid, heat and trypsin.82 The glycosyl functionalised polymers
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osaccharide polymers, had no activity,
active but homopolymers less so than
mide.
ically or physically crosslinked
have been linked to a variety of
delivery applications. Nakamae et al.
gels by polymerising the glycosylated
osyloxy)ethyl methacrylate in the
rosslinker and the lectin concanavalin
to the chemical crosslinking provided
r, physical crosslinking is provided by
of Con A leads to gels displaying
and mannose) with swelling increasing
ation as this displaces the polymeric
A binding site resulting in reduced
ntly, such materials display promise as
or as drug-delivery devices for insulin
vels would promote the release of the
uced glycohydrogels for the treatment
n, one of the main causes of
uses have been demonstrated to bind to
erythrocytes that determine the blood
affinity to the B group epitope. They
er 1-acrylamido-3,6-dioxa-8-octyl-O-
2)-O-(-D-galactopyranosyl)-(13)--D-
subsequently polymerised it in the
e, diallyldimethylammonium chloride
sacrylamide to yield hydrogels of the
13. The entrapment ability of the
espect to norovirus was determined
us-like particles, virus particles that
ELISA assays. Glycohydrogels were
ically the solution virus concentration
ls prepared in the absence of the
85
een investigated in several areas of
therapeutic development and delivery. Despite considerable45
potential it must be noted that the majority of the studies
discussed are preliminary – many have not been pursued
beyond simple in vitro studies – and extensive research is still
required if glycopolymer-based therapeutics are to reach the
clinic.50
The most advanced example, that of PK2, was found to be
unsatisfactory for its planned target but has demonstrated that
it is possible to produce a relatively complex drug-conjugate
to a standard that permits clinical evaluation, that is cGMP.
PK2 was synthesised using methodologies that much of the55
synthetic polymer community would now consider archaic
and ill-defined but their simplicity may be an advantage in
seeking FDA, or equivalent, approval. Combined with the
advances in polymerisation technologies that have occured
over recent decades the production of materials of consistent,60
defined quality may allow translation of some of
aforementioned examples to clinical development.
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